Abstract
AlesionⓇ eyelid cream 0.5％ is a cream-type anti-allergic conjunctivitis agent that is applied to the eyelid. Approval was obtained in March 2024, and domestic sale began in May of the same year. Unlike conventional eye drops, it is a formulation with the new concept that cream is applied to the eyelid and then acts persistently on the conjunctiva via the skin of the eyelid. Traditionally in the treatment of allergic conjunctivitis, topical eye drops（a histamine H1 receptor antagonist and an inhibitor of chemical mediator release） administered twice or four times daily are the mainstay, but this product can be treated with once-daily application by delivering active ingredient to the conjunctiva through the eyelid. In addition, this product is expected to be a new dosage form that can resolve various problems caused by instillation behavior（difficulty in turning upward when instilling eye drops, inability to get into the eyedrop successfully, spillage of this product solution from the eye after instillation, etc.）. This article presents the developmental history, characteristics of this product, differences from conventional eye drop treatment and preclinical study findings.
